Bio-Path Holdings, Inc.
BPTH
Rank in Stocks
#34481
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on... Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Share Price
$0.0003
Last synced: 2026-11-09
Market Cap
$15.09K
Change (1 day)
0.00%
Change (1 year)
-99.65%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Bio-Path Holdings, Inc. (BPTH)
Category
Healthcare
EPS for Bio-Path Holdings, Inc. (BPTH)
EPS as of June 2026 TTM: $-0.25
According to Bio-Path Holdings, Inc.'s latest financial reports, its current EPS (TTM) is $-0.25. At the end of 2025 the company had an EPS of $-1.10, an increase over its 2024 EPS of $-4.12.
EPS history for Bio-Path Holdings, Inc. from 2004 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.25 | -77.27% |
| 2025 | $-1.10 | -73.30% |
| 2024 | $-4.12 | -87.75% |
| 2023 | $-33.64 | -11.54% |
| 2022 | $-38.03 | 22.52% |
| 2021 | $-31.04 | -45.00% |
| 2020 | $-56.44 | -11.84% |
| 2019 | $-64.02 | -77.74% |
| 2018 | $-287.54 | 3.18% |
| 2017 | $-278.69 | -4.32% |
| 2016 | $-291.26 | 19.56% |
| 2015 | $-243.61 | 20.30% |
| 2014 | $-202.50 | 10.63% |
| 2013 | $-183.04 | 5.10% |
| 2012 | $-174.15 | -0.81% |
| 2011 | $-175.57 | 1.54% |
| 2010 | $-172.91 | -7.07% |
| 2009 | $-186.06 | -32.88% |
| 2008 | $-277.22 | 7,119.27% |
| 2007 | $-3.84 | -72.82% |
| 2006 | $-14.13 | 3.06% |
| 2005 | $-13.71 | 27.53% |
| 2004 | $-10.75 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -6,364.00% |
US
|
|
| $-7.07 | 2,728.00% |
US
|
|
| $-5.29 | 2,016.00% |
AU
|
|
| $12.88 | -5,252.04% |
BE
|
|
| $21.56 | -8,724.00% |
NL
|
Questions about Bio-Path Holdings, Inc.'s earnings per share (EPS)
What is Bio-Path Holdings, Inc.'s earnings per share (EPS)?
Bio-Path Holdings, Inc.'s earnings per share (EPS) over the last twelve months is $-0.25, as of Jun 2026.
What was Bio-Path Holdings, Inc.'s earnings per share (EPS) in 2025?
In 2025, Bio-Path Holdings, Inc.'s earnings per share (EPS) was $-1.10, compared with $-4.12 in 2024.
How has Bio-Path Holdings, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Bio-Path Holdings, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.10) and lowest in 2020 ($-56.44).
How does Bio-Path Holdings, Inc.'s earnings per share (EPS) compare with similar companies?
Bio-Path Holdings, Inc.'s earnings per share (EPS) ($-0.25) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.